NVO - Eli Lilly's Commercial Moat Competitor Landscape: BofA Emphasizes Strength in Incretin Space Undervalued Assets | Benzinga
BofA Securities says Eli Lilly and Company (NYSE:LLY) remains a top choice in Biopharma analysis, boasting a remarkable year-to-date performance of +29% (compared to the DRG index’s +10%).
The U.S. pharma giant continues to shine in the biopharma sector, which is attributable to outstanding revenue growth, expanding margins, and a promising pipeline compared to peers.
Also Read: Large US Drug Makers Highlight Indian Market For Their Blockbuster Drugs Including For Weight Loss.
While the market acknowledges the potential of Mounjaro (diabetes) and Zepbound (obesity), BofA asserts that opportunities in heart disease, obstructive sleep apnea, and liver disease are significantly undervalued.
BofA Securities has increased its price target to $1000 from $800, incorporating undervalued opportunities and the next-gen GLP-1 oral (orforglipron).